PMC:7784830 / 24092-24224 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"402","span":{"begin":14,"end":46},"obj":"Disease"},{"id":"403","span":{"begin":48,"end":52},"obj":"Disease"}],"attributes":[{"id":"A402","pred":"tao:has_database_id","subj":"402","obj":"MESH:D018352"},{"id":"A403","pred":"tao:has_database_id","subj":"403","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Novavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology."}

{"project":"LitCovid-sentences","denotations":[{"id":"T191","span":{"begin":0,"end":132},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Novavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology."}